HRP20070328T3 - SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI - Google Patents

SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI

Info

Publication number
HRP20070328T3
HRP20070328T3 HR20070328T HRP20070328T HRP20070328T3 HR P20070328 T3 HRP20070328 T3 HR P20070328T3 HR 20070328 T HR20070328 T HR 20070328T HR P20070328 T HRP20070328 T HR P20070328T HR P20070328 T3 HRP20070328 T3 HR P20070328T3
Authority
HR
Croatia
Prior art keywords
group
groups
alkyl
optionally substituted
alkyl group
Prior art date
Application number
HR20070328T
Other languages
English (en)
Inventor
Chereze Nathalie
Lochead Alistair
Saady Mourad
Slowinski Franck
Yaiche Philippe
Original Assignee
Sanofi-Aventis
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis, Mitsubishi Pharma Corporation filed Critical Sanofi-Aventis
Publication of HRP20070328T3 publication Critical patent/HRP20070328T3/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/141—Feedstock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Dihidrospiro[cikloalkilamin]pirimidonski derivati, prikazani formulom (I) ili njegova sol, ili njensolvat ili hidrat: naznačen time što: X predstavlja dva atoma vodika, atom sumpora, atom kisika iliC1-2 alkilnu skupinu i atom vodika; Y predstavljavezu, karbonilnu skupinu, metilensku skupinu, izborno supstituiranu s jednom ili dvije skupine, koje se bira između C1-6 alkilne skupine, hidroksilneskupine, C1-4 alkoksi skupine, perhalogenirane C1-2 alkilne skupine ili amino skupine; R1 znači 2-,3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, prsten izborno supstituiran s C1-4alkilnom skupinom, C1-4 alkoksi skupinom ili atomom halogena; R2 predstavlja benzenski prsten ili naftalenski prsten; prstene izborno supstituiran s 1 do 4 supstituenta, koje se bira između C1-6 alkilne skupine, metilendioksi skupine, atoma halogena, perhalogenirane C1-2 alkilne skupine, halogenirane C1-3 alkilne skupine, hidroksilne skupine, C1-4alkoksi skupine, nitro, cijano, amino, C1-5 monoalkilamino skupine ili C2-10 dialkilamino skupine; R3 predstavlja atom vodika, C1-6 alkilnu skupinu ili atom halogena; R4 predstavlja atom vodika, C1-4alkoksikarbonilnu skupinu, C3-6 cikloalkilkarbonilnu skupinu, benzoilnu skupinu, C1-6 alkilnu skupinu, gdje su te skupine izborno supstituiran s 1 do4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C1-4 alkoksi skupine; oi m znače 1 do 2; n znači 0 do 3; p znači 0 do 2;iq znači 0 do 2. Patent sadrži još 12 patentnih zahtjeva.
HR20070328T 2003-12-19 2007-07-17 SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI HRP20070328T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03293236A EP1557417B1 (en) 2003-12-19 2003-12-19 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
PCT/EP2004/014846 WO2005058908A1 (en) 2003-12-19 2004-12-17 SUBSTITUTED 8’-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
HRP20070328T3 true HRP20070328T3 (hr) 2008-03-31

Family

ID=34626443

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070328T HRP20070328T3 (hr) 2003-12-19 2007-07-17 SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI

Country Status (29)

Country Link
US (2) US7294631B2 (hr)
EP (2) EP1557417B1 (hr)
JP (1) JP4896734B2 (hr)
KR (1) KR20060127055A (hr)
CN (1) CN1914208B (hr)
AR (1) AR047056A1 (hr)
AT (1) ATE360632T1 (hr)
AU (1) AU2004299285B2 (hr)
BR (1) BRPI0417208A (hr)
CA (1) CA2550168A1 (hr)
CY (1) CY1107982T1 (hr)
DE (1) DE602004006169T2 (hr)
DK (1) DK1699795T3 (hr)
EA (1) EA010419B1 (hr)
ES (1) ES2286707T3 (hr)
HK (1) HK1096401A1 (hr)
HR (1) HRP20070328T3 (hr)
IL (1) IL176287A0 (hr)
ME (1) MEP21408A (hr)
MX (1) MXPA06006931A (hr)
NO (1) NO20063187L (hr)
NZ (1) NZ547956A (hr)
PL (1) PL1699795T3 (hr)
PT (1) PT1699795E (hr)
RS (1) RS50519B (hr)
SI (1) SI1699795T1 (hr)
TW (1) TWI346664B (hr)
WO (1) WO2005058908A1 (hr)
ZA (1) ZA200604960B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014970A1 (es) * 2005-07-29 2007-02-08 Universidad De Barcelona Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP1921080B1 (en) * 2006-11-07 2009-08-05 Sanofi-Aventis Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2090578A1 (en) 2008-01-29 2009-08-19 Sanofi-Aventis Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta
EP2085400A1 (en) 2008-01-29 2009-08-05 Sanofi-Aventis Substituted heteroarylamide oxazepinopyrimidone derivatives
EP2085399A1 (en) 2008-01-29 2009-08-05 Sanofi-Aventis substituted arylamide oxazepinopyrimidone derivatives
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8446810B2 (en) 2008-10-01 2013-05-21 Panasonic Corporation Information recording medium having recording condition for adjusting the position of cooling pulse
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BRPI1015943A8 (pt) 2009-07-02 2018-01-09 Sanofi Sa derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2018163216A1 (en) * 2017-03-10 2018-09-13 Council Of Scientific & Industrial Research Spirooxindole compounds as gsk3β inhibitors and process for preparation thereof
CN112694478A (zh) * 2020-12-24 2021-04-23 绍兴文理学院 一种硝基取代含哒嗪酮结构的螺吡唑-吡咯里嗪衍生物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335992A (en) * 1996-12-05 2001-09-28 Amgen Inc Substituted pyrimidinone and pyridone compounds and methods of use
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
EP1340761A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
BR0212904A (pt) * 2001-09-21 2004-10-13 Sanofi Synthelabo Derivados substituìdos de 2-pirimidinil-6,7,8,9-tetraidropirimido-{1,2-a}pirimidin- 4-ona e 7-pirimidinil-2,3-diidroimidazo-{1,2-a}pirimi-din-5(1h)-on a para distúrbios neurodegenerativos
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP1340760A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
NZ547205A (en) * 2001-09-21 2007-11-30 Sanofi Aventis Intermediates of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
SI1480983T1 (sl) * 2002-02-28 2006-04-30 Sanofi Aventis Heteroarilno substituirani 2-piridinil in 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-onski derivati
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors

Also Published As

Publication number Publication date
DK1699795T3 (da) 2007-09-10
US20070010539A1 (en) 2007-01-11
BRPI0417208A (pt) 2007-02-06
CY1107982T1 (el) 2013-09-04
CN1914208B (zh) 2010-12-22
EP1557417B1 (en) 2007-03-07
KR20060127055A (ko) 2006-12-11
SI1699795T1 (sl) 2007-10-31
JP2007514707A (ja) 2007-06-07
NO20063187L (no) 2006-09-19
EA200601192A1 (ru) 2006-10-27
EP1699795A1 (en) 2006-09-13
PL1699795T3 (pl) 2008-01-31
NZ547956A (en) 2010-03-26
AU2004299285A1 (en) 2005-06-30
US20080081820A1 (en) 2008-04-03
AU2004299285B2 (en) 2010-03-18
ES2286707T3 (es) 2007-12-01
DE602004006169T2 (de) 2008-01-10
CN1914208A (zh) 2007-02-14
RS50519B (sr) 2010-05-07
ATE360632T1 (de) 2007-05-15
EP1557417A1 (en) 2005-07-27
US7294631B2 (en) 2007-11-13
HK1096401A1 (en) 2007-06-01
MXPA06006931A (es) 2007-04-24
MEP21408A (en) 2010-06-10
TWI346664B (en) 2011-08-11
PT1699795E (pt) 2007-08-03
IL176287A0 (en) 2006-10-05
US7547705B2 (en) 2009-06-16
CA2550168A1 (en) 2005-06-30
EP1699795B1 (en) 2007-04-25
JP4896734B2 (ja) 2012-03-14
EA010419B1 (ru) 2008-08-29
DE602004006169D1 (de) 2007-06-06
TW200530247A (en) 2005-09-16
AR047056A1 (es) 2006-01-04
WO2005058908A1 (en) 2005-06-30
ZA200604960B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
HRP20070328T3 (hr) SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI
CY1109345T1 (el) ΠΑΡΑΓΩΓΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8-ΥΠΕΡΦΘΟΡΟΑΛΚΥΛΟ-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ (1,2-a) ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
RS51654B (en) DERIVATIVES OF THE SUBSTITUTED BICYCLIC PIRIMIDONE
AR057914A1 (es) Compuestos organicos de azufre y su uso
WO2006032466A3 (en) New bicyclic antibiotics
AR049331A1 (es) Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas.
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
MEP8409A (en) Fused heterocyclic compound
EA200971063A1 (ru) Ариламидпиримидоновые соединения
PE120999A1 (es) Piridinas, piridazinas, pirimidinas y pirazinas biciclicas
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
RS52307B (en) CONDENSED CYCLIC UNITS
EA200971062A1 (ru) Производные ариламидпиримидона
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
ATE401311T1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
EA200300151A1 (ru) ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА И 7-ПИРИДИНИЛ-2,3-ДИГИДРОИМИДАЗО[1,2-a]ПИРИМИДИН-5(1H)ОНА
DE60327922D1 (de) Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE60326933D1 (de) Kondensierte bicyclische pyrimidinderivate
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
EA200400867A2 (ru) Новые соединения гетероциклического оксима, способ их получения и фармацевтические композиции, содержащие их
MXPA03000341A (es) Derivados de variolina como agentes anit-cancer.
DK1501838T3 (da) Fremgangsmåde til fremstilling af clopidogrel